Activation Relay on Rhodium-Catalyzed C–H Aminomethylation in Cooperation with Photoredox Catalysis
作者:Ruixing Liu、Jiaxin Liu、Yin Wei、Min Shi
DOI:10.1021/acs.orglett.9b01261
日期:2019.6.7
A site selective C–H aminomethylation at indole’s C3 position has been achieved by merging rhodium(III)-catalyzed C–H activation and photoredox catalysis in a one-pot manner. An investigation of the mechanistic insights rationalized the essence of the activation relay and the combination mode.
highly selective C-2 difluoromethylation of indole derivatives was developed by using sodium difluoromethylsulfinate (HCF2SO2Na) as the source of difluoromethyl groups and a Cu(II) complex as the catalyst. Various substrates were well tolerated in this transformation and the desired products were obtained in moderate to good yields. Moreover, the late-stage C-2 difluoromethylation of bioactive molecules
通过使用二氟甲基亚磺酸钠(HCF 2 SO 2 Na)作为二氟甲基的来源和Cu(II)络合物作为催化剂,开发了一种新颖且高效的吲哚衍生物高选择性C-2二氟甲基化方法。在这种转化中,各种底物都具有良好的耐受性,并且以中等至良好的产率获得了所需的产物。此外,以高收率实现了含有吲哚环的生物活性分子的后期C-2二氟甲基化。通常,该反应具有出色的官能团相容性,广泛的底物范围和出色的C-2选择性。
Direct Hiyama Cross-Coupling of (Hetero)arylsilanes with C(sp<sup>2</sup>)–H Bonds Enabled by Cobalt Catalysis
We report a chelation-assisted C–H arylation of various indoles with sterically and electronically diverse (hetero)arylsilanes enabled by cost-effective Cp*-free cobaltcatalysis. Key to the success of this strategy is the judicious choice of copper(II) fluoride as a bifunctional sliane activator and catalyst reoxidant. This methodology features a broad substrate scope and good functional group compatibility
[EN] SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES<br/>[FR] AMINES BICYCLIQUES SUBSTITUÉES POUR LE TRAITEMENT DU DIABÈTE
申请人:MERCK SHARP & DOHME
公开号:WO2010056717A1
公开(公告)日:2010-05-20
Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.